A randomised, placebo-controlled phase IIb clinical trial of CTX cell therapy candidate (ReN 001) for stroke disability.

Trial Profile

A randomised, placebo-controlled phase IIb clinical trial of CTX cell therapy candidate (ReN 001) for stroke disability.

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs ReN 001 (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms PISCES III
  • Most Recent Events

    • 21 Dec 2017 New trial record
    • 14 Dec 2017 According to a ReNeuron media release, the US FDA has given regulatory approval to commence a Phase IIb clinical study in the US. Data from the study are expected in late 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top